Najít Technologies, Inc. (NTI) was founded in 2004 to commercialize diagnostics and vaccine technologies developed at Oregon Health & Science University in Portland, Oregon. The company's focus is to develop safe and effective vaccines for emerging and re-emerging infectious diseases. Moreover, our approach will benefit previously underserved and vulnerable populations, such as the very young, the elderly, and the immunocompromised . With increased safety and immunogenicity, our vaccine platform also better serves the general population. Our strategy is to develop vaccines that fit the unmet needs of these market segments in addition to military and civilian travelers who need safe but highly effective vaccines against potentially life-threatening infectious diseases in endemic countries.

We have developed an exciting new vaccine platform to address these markets.

HydroVAX

NTI utilizes a novel vaccine platform technology that results in superior inactivated vaccine formulations for infectious disease as compared to conventional methods.

HydroVAX vaccines:
  1. replace live attenuated vaccines, thus reducing the chances for rare but serious adverse events in vaccinated individuals.
  2. preserve important immunologic epitopes, including neutralizing epitopes and T cell epitopes in a manner that is superior to conventional methods.
  3. are amenable to preservative-free vaccine formulations.
Please see Technologies for more information on products being developed from these platforms.